EurekaMag.com logo
+ Site Statistics
References:
54,215,046
Abstracts:
30,230,908
PMIDs:
28,215,208
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Recurrent exacerbation of acne by granulocyte colony-stimulating factor administration



Recurrent exacerbation of acne by granulocyte colony-stimulating factor administration



Journal of the American Academy of Dermatology 34(5 Pt 1): 855-856




(PDF emailed within 0-6 h: $19.90)

Accession: 033119606

Download citation: RISBibTeXText

PMID: 8632088

DOI: 10.1016/s0190-9622(96)90045-6



Related references

Chronic recurrent multifocal osteomyelitis with Crohn's disease exacerbation and vasculitis after granulocyte colony-stimulating factor therapy. Journal of Clinical Rheumatology 6(5): 283-290, 2000

Expression of granulocyte-colony-stimulating factor and its receptor in human Ewing sarcoma cells and patient tumor specimens: potential consequences of granulocyte-colony-stimulating factor administration. Cancer 110(7): 1568-1577, 2007

Modulation of neonatal rat myeloid kinetics resulting in peripheral neutrophilia by single pulse administration of Rh granulocyte-macrophage colony-stimulating factor and Rh granulocyte colony-stimulating factor. Biology of the Neonate 59(1): 13-21, 1991

Concurrent administration of granulocyte colony-stimulating factor or granulocyte-monocyte colony-stimulating factor enhances the biological activity of rituximab in a severe combined immunodeficiency mouse lymphoma model. Leukemia & Lymphoma 46(12): 1775-1784, 2005

Effects of administration of progenipoietin 1, Flt-3 ligand, granulocyte colony-stimulating factor, and pegylated granulocyte-macrophage colony-stimulating factor on dendritic cell subsets in mice. Blood 99(6): 2122-2130, 2002

Therapeutic efficacy of the combined administration of either recombinant human interleukin-6 and rh Granulocyte colony stimulating factor or rh Granulocyte-macrophage colony stimulating factor in a primate model of radiation-induced marrow aplasia. Experimental Hematology (Charlottesville) 22(8): 684, 1994

Phase I/II study of combined granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor administration for the mobilization of hematopoietic progenitor cells. Journal of Clinical Oncology 14(1): 277-286, 1996

Effects on spleen colony forming unit self renewal after retroviral mediated gene transfer of multi colony stimulating factor granulocyte macrophage colony stimulating factor or granulocyte colony stimulating factor. Experimental Hematology (Charlottesville) 19(7): 604-607, 1991

Concurrent Administration of Granulocyte Colony-Stimulating Factor or Granulocyte-Monocyte Colony-Stimulating Factor Enhance Rituximabs Biological Activity and Upregulate CD11b in a Severe Combined Immunodeficiency Mouse Lymphoma Model. Blood 100(11): Abstract No 588, November 16, 2002

In vivo administration of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor increases neutrophil oxidative burst activity. Journal of Interferon & Cytokine Research 15(3): 249-253, 1995

Granulocyte colony-stimulating factor serum and urine concentrations in neutropenic neonates before and after intravenous administration of recombinant granulocyte colony-stimulating factor. Pediatrics 105(2): 392-397, 2000

A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products. Biology of Blood and Marrow Transplantation 10(12): 848-857, 2004

Chemotherapy with granulocyte colony stimulating factor (G-CSF) alone versus granulocyte colony stimulating factor (G-CSF) plus granulocyte-macrophage stimulating factor (GM-CSF) for hematopoietic progenitor cell mobilization in patients with relapsed non-hodgkin's lymphomas (NHLs).. 2007